Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, ...
Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...
After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going ...
The European Union’s upcoming Biotech Act is hotly anticipated in the world of food. The Act could be integral to food innovation, streamlining regulation in areas such as precision fermentation. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results